74 related articles for article (PubMed ID: 12089352)
1. Cloning of the mouse insulin receptor substrate-3 (mIRS-3) promoter, and its regulation by p53.
Sciacchitano S; Orecchio A; Lavra L; Misiti S; Giacchini A; Zani M; Danese D; Gurtner A; Soddu S; Di Mario U; Andreoli M
Mol Endocrinol; 2002 Jul; 16(7):1577-89. PubMed ID: 12089352
[TBL] [Abstract][Full Text] [Related]
2. Characterization and regulation of the mouse insulin receptor substrate gene promoter.
Araki E; Haag BL; Matsuda K; Shichiri M; Kahn CR
Mol Endocrinol; 1995 Oct; 9(10):1367-79. PubMed ID: 8544845
[TBL] [Abstract][Full Text] [Related]
3. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
4. Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y.
Pospísilová S; Siligan C; Ban J; Jug G; Kovar H
Mol Cancer Res; 2004 May; 2(5):296-304. PubMed ID: 15192123
[TBL] [Abstract][Full Text] [Related]
5. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
7. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer.
Webster NJ; Resnik JL; Reichart DB; Strauss B; Haas M; Seely BL
Cancer Res; 1996 Jun; 56(12):2781-8. PubMed ID: 8665514
[TBL] [Abstract][Full Text] [Related]
8. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.
Unger T; Juven-Gershon T; Moallem E; Berger M; Vogt Sionov R; Lozano G; Oren M; Haupt Y
EMBO J; 1999 Apr; 18(7):1805-14. PubMed ID: 10202144
[TBL] [Abstract][Full Text] [Related]
9. Survivin regulates the p53 tumor suppressor gene family.
Wang Z; Fukuda S; Pelus LM
Oncogene; 2004 Oct; 23(49):8146-53. PubMed ID: 15361831
[TBL] [Abstract][Full Text] [Related]
10. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1- and IRS-2-mediated signaling.
Tsuruzoe K; Emkey R; Kriauciunas KM; Ueki K; Kahn CR
Mol Cell Biol; 2001 Jan; 21(1):26-38. PubMed ID: 11113178
[TBL] [Abstract][Full Text] [Related]
11. Identification of a tumor-derived p53 mutant with novel transactivating selectivity.
Pan Y; Haines DS
Oncogene; 2000 Jun; 19(27):3095-100. PubMed ID: 10871862
[TBL] [Abstract][Full Text] [Related]
12. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.
Gottlieb E; Haffner R; King A; Asher G; Gruss P; Lonai P; Oren M
EMBO J; 1997 Mar; 16(6):1381-90. PubMed ID: 9135153
[TBL] [Abstract][Full Text] [Related]
13. [Characterization of the IRS-1 (insulin receptor substrate-1) gene and its promoter].
Araki E; Kahn CR; Shichiri M
Nihon Rinsho; 1994 Oct; 52(10):2659-64. PubMed ID: 7983795
[TBL] [Abstract][Full Text] [Related]
14. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
15. p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53.
Ori A; Zauberman A; Doitsh G; Paran N; Oren M; Shaul Y
EMBO J; 1998 Jan; 17(2):544-53. PubMed ID: 9430645
[TBL] [Abstract][Full Text] [Related]
16. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
Jones SN; Roe AE; Donehower LA; Bradley A
Nature; 1995 Nov; 378(6553):206-8. PubMed ID: 7477327
[TBL] [Abstract][Full Text] [Related]
17. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
18. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional repression of taurine transporter gene (TauT) by p53 in renal cells.
Han X; Patters AB; Chesney RW
J Biol Chem; 2002 Oct; 277(42):39266-73. PubMed ID: 12163498
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M; Berberich SJ
Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
